The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic levels, however, challenges such as rapid renal clearance, degradation or non-specific accumulation requires drug delivery enabling technologies. Albumin is a natural transport protein with multiple ligand binding sites, cellular receptor engagement, and a long circulatory half-life due to interaction with the recycling neonatal Fc receptor. Exploitation of these properties promotes albumin as an attractive candidate for half-life extension and targeted intracellular delivery of drugs attached by covalent conjugation, genetic fusions, association or ligand-mediated association. This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.

UC patients with CRC have a stage distribution similar to patients with CRC without UC. The prognosis of CRC is poorer for UC patients than for patients without UC.

In analyzing data from a register-based cohort study in Denmark, we found that inviting individuals to undergo FIT-based CRC screening led to detection of almost 2-fold more cases of CRC than not inviting participants. The significant increase of CRC incidence among those invited for screening indicates a need for awareness of treatment capacity in countries introducing FIT-based CRC screening.

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, we report on the significant progress being made by advocates to raise the legal purchase age for buying tobacco products in the US. We also look at a recent study that reveals advanced cancer patients' negative responses to the use of computer screens in the examination room, and another study that highlights the potential of pairing cognitive computing and genomics to improve cancer treatment. After gynecologic risk-reducing surgery, BRCA1/2 mutation carriers remain at risk of developing primary peritoneal cancer. The study by Harmsen et al in this issue of Cancer provides information regarding who might be at greater risk after risk-reduction surgery. Thyroid nodules affect nearly two-thirds of the world population. Cytology alone, in the form of fine-needle aspiration, fails to classify thyroid nodules in up to one-third of cases. This review investigates the limitation of current evaluation techniques and the development of thyroid molecular testing, and it specifically discusses the strengths and limitations of currently available molecular tests. In this large population-based study, the overall rates per 1000 person-years are 0.65 for acute myeloid leukemia (AML) and 1.56 for myelodysplastic syndrome (MDS). Patients who receive an anthracycline or an anthracycline and taxane regimen are more likely to develop AML or MDS than patients who do not receive chemotherapy. Patients treated with docetaxel and cyclophosphamide are not at increased risk for AML or MDS. The government could improve screening rates by training case managers to assist in following patients until they have completed colonoscopy, subsidizing sedated colonoscopies, and providing health education not only to the general public but also to physicians. Conditional survival estimates for Chinese patients with gastric cancer increase with time elapsed, and those who have unfavorable tumor characteristics have the greatest improvement in conditional survival. This valuable information could provide more precise long-term prognostic evaluation and may serve as an important prognostic index in clinical practice. The current trial-level meta-analysis of 13 randomized controlled trials of adjuvant systemic therapies in patients with non-metastatic renal cell carcinoma reports only a modest correlation between 5-year disease-free survival and 5-year overall survival (R-squared, 0.48) and between the treatment effects (R-squared, 0.44) on these endpoints. These results underscore the need to identify alternative clinical and biologic metrics that can more rapidly assess clinical outcomes and hasten drug development in areas of unmet need such as non-metastatic renal cell carcinoma. Stereotactic ablative radiotherapy is well tolerated and effective for primary renal cell carcinoma with an acceptable impact on renal function. Patients who receive single-fraction stereotactic ablative radiotherapy appear to be...